ESG

A landmark report reveals corporate commitment to women's advancement is plummeting, creating an ambition gap that threatens to erase a decade of progress.

A top global forum warns of politicized trade and tech divides. How will this impact pharma supply chains, AI in medicine, and market access?

A Japanese chemical plant's new AI-powered microgrid reveals how firms are using renewables not just for ESG, but as a defense against disaster and grid failure.

A deep dive into 22 Fulton Street, where complex finance, green design, and affordable housing converge to reshape Newark's skyline and its community.

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

The biggest obstacle to the EV revolution might be under your feet. One company's simple, award-winning solution to a muddy problem is changing the game.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A cub’s rescue reveals more than a conservation win; it showcases China's massive investment in 'ecological civilization' as a core economic strategy.

A new point-of-care PCR test is moving closer to reality in India, promising to revolutionize the fight against tuberculosis and cervical cancer.

A Chinese wood product firm's new German website reveals a strategic blueprint for B2B market entry, testing the power of digital localization.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

75% of employees say pet health impacts their work stress. Discover why pet benefits are no longer a perk, but a key strategy for productivity and talent retention.

The biotech is advancing a promising myelofibrosis therapy while developing a next-gen 'super drug,' a dual strategy signaling significant growth.

A South Korean biotech's novel antibody, now named rapaprutug, could shift the paradigm for pulmonary arterial hypertension by targeting its root causes.

For the fifth year, GCM Grosvenor is a top workplace. We explore how their people-first strategy is a key asset in the competitive world of finance.